SCHEMBL3662756

SCHEMBL3662756

COc1ccc(Br)cc1C(=O)NC1CNCCn2c1nc(-c1ccncn1)cc2=O

nearest known ligand 0.44

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
GSK3B P49841 19/20 0.44
CYP2D6 P10635 4/20 0.37
CYP1A2 P05177 2/20 0.37
ALDH1A1 P00352 1/20 0.37
CYP3A4 P08684 1/20 0.37
CYP2C9 P11712 1/20 0.37
CYP2C19 P33261 1/20 0.37
HTT P42858 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37
TDP1 Q9NUW8 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3666557 0.91 GSK3B (0.44) GSK3BCYP2D6CYP1A2
SCHEMBL3662859 0.90 GSK3B (0.45) GSK3BCYP2D6CYP1A2
SCHEMBL2064918 0.89 DRD2 (0.43) GSK3BCYP2D6CYP1A2ALDH1A1CYP3A4
SCHEMBL2065404 0.88 MEN1 (0.41) GSK3BCYP2D6CYP1A2ALDH1A1CYP3A4
SCHEMBL3661580 0.88 GSK3B (0.44) GSK3BCYP2D6CYP1A2CYP3A4
SCHEMBL3664336 0.87 GSK3B (0.44) GSK3BCYP2D6CYP1A2CYP3A4
SCHEMBL3661728 0.86 GSK3B (0.44) GSK3BCYP2D6CYP1A2
SCHEMBL3402010 0.86 GSK3B (0.39) GSK3BCYP2D6CYP1A2ALDH1A1CYP3A4
SCHEMBL3663726 0.86 GSK3B (0.44) GSK3BCYP2D6CYP1A2TDP1
SCHEMBL3666453 0.86 GSK3B (0.47) GSK3BCYP2D6CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2238141-A1 SUBSTITUTED ARYLAMIDE DIAZEPINOPYRIMIDONE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES CAUSED BY ABNORMAL ACTIVITY OF GSK3-BETA Sanofi-Aventis (FR) 2010-10-13 EP disclosed
WO-2009095789-A1 SUBSTITUTED ARYLAMIDE DIAZEPINOPYRIMIDONE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES CAUSED BY ABNORMAL ACTIVITY OF GSK3-BETA SANOFI-AVENTIS (FR) 2009-08-06 WO disclosed